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The main aim of surgery in treating any cancer is to 
completely excise the tumour, thereby preventing local 
recurrence. In the case of melanoma, the purpose of a 
wide excision is to remove local micrometastases and 
otherwise phenotypically normal tissue that might 
be harbouring genotypically abnormal cells located in 
either the surrounding cutis or superﬁ cial lymphatics, 
while at the same time trying to prevent unacceptable 
functional and cosmetic harm to the patient as a result.
In The Lancet Oncology, Andrew Hayes and colleagues1 
report the long term follow-up data from the UK 
excision margins trial,4 which started in 1993. 
The original work has been included in meta-analyses, 
and the data have been key in producing international 
guidance on the surgical management of melanoma. 
The latest analysis of the data1 suggests that the 
narrower excision margin of 1 cm is associated with 
worse disease-speciﬁ c survival, estimated as an absolute 
diﬀ erence of 5·95% (95% CI –0·54 to 12·44) at 10 years, 
compared with that in patients who had the wider 3 cm 
excision margin at a median follow-up of 8·8 years: 
(unadjusted hazard ratio [HR] 1·24 [95% CI 1·01–1·53], 
p=0·041).
These data are important because they seem to 
contrast with ﬁ ndings from ﬁ ve other randomised trials 
suggesting that narrow margins around melanomas 
(1 cm or 2 cm) are just as safe as wide ones (3 cm, 4 cm, 
or 5 cm).2 Currently, only the UK national guidelines3 
continue to recommend 3 cm margins around thicker 
primary melanomas, compared with guidelines from 
other countries that recommend 2 cm as the maximum 
margin. Hayes and colleagues propose that the ﬁ ndings 
in their long-term analysis are linked directly to their 
previous ﬁ nding of increased locoregional recurrence 
associated with the narrower 1 cm excision margin 
compared with the 3 cm excision margin.4 However, in 
both surgical groups, the incidence of nodal recurrence 
outweighed the incidence of local recurrence by at least 
5 to 1. In view of the ﬁ ndings of the MSLT-1 study,5 in 
which the incidence of sentinel node positivity matched 
the number of nodal recurrences, especially for thick 
melanomas, most of these nodal metastases would 
probably have been detected by sentinel-node biopsy, 
if it had been done at the time of the intervention. 
Accordingly, a plausible alternative explanation is that 
the excess nodal disease in the narrow margin group 
was indicative of poor prognostic disease before the 
intervention, rather than resulting from the narrow 
margin intervention itself.
The overall recurrence data, including data for 
in-transit metastases, from the primary analysis4 
were remarkably similar between the 1 cm and 3 cm 
groups (5·7% vs 4·7%). However, when analysed as 
a speciﬁ c secondary endpoint, the diﬀ erence in local 
recurrence between the groups was greater, although 
not signiﬁ cantly (8·2% vs 5·6%; HR 1·51 [95% CI 
0·91–2·51]; p=0·1).4 Since 2004, it has become clear 
that the presence of microsatellites—representing 
microscopic, discontiguous, intralymphatic extensions 
of melanoma directly adjacent to the primary tumour—
is a poor prognostic indicator for melanoma, and 
is now classiﬁ ed as stage III disease.6 Whether an 
excess of microsatellites was present in the 1 cm 
group before or at randomisation in the present 
study is unclear, because this information was not 
included in the standard synoptic report at the time. 
Nevertheless, the evidence could be signalling that 
the 1 cm excision margin might be inadequate to 
deal with microsatellites in particular. Data from the 
recent Scandinavian wide excision trial7 is consistent 
with this notion, because local recurrence was higher 
in the narrow margin group (2 cm) than in the wide 
margin group (4 cm), although this was not signiﬁ cant. 
Data from a large, retrospective study investigating risk 
factors for locoregional recurrences8 have suggested 
that in-transit metastases and local recurrences are 
associated with an increased incidence of subsequent 
regional nodal relapse, despite an initially negative 
sentinel node.
In summary, the implication of Hayes and colleagues’ 
study is that high-risk melanoma phenotypes might 
be unmasked by a narrower, 1 cm wide-excision 
margin around tumours and these risks could manifest 
as clinically detectable local or regional recurrences 
(or both) in follow-up. Closer inspection of the data, 
however, suggests that this subgroup of patients is small 
and that most patients could be safely managed without 
creating 4–6 cm wide excision defects. A multinational, 
phase 3 clinical trial in progress aims to conﬁ rm this 
(NCT02385214). Accordingly, clinicians’ eﬀ orts might 
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The risk of an underlying malignant disease is increased 
in patients presenting with unprovoked venous 
thromboembolism, particularly with increasing age, 
with an estimated prevalence of hidden cancer of around 
10%.1,2 Although, at least theoretically, workup for occult 
cancer in this scenario could lead to early diagnosis and 
reduce cancer-related mortality, this hypothesis has not 
yet been conﬁ rmed.3 Indeed, conducting a randomised 
trial on this topic is not an easy task, because there are 
plenty of methodological diﬃ  culties to face. 
The recently published SOME study4 concluded that, 
in patients with unprovoked venous thromboembolism, 
routine screening with comprehensive CT of the 
abdomen and pelvis (including virtual gastroscopy 
and colonoscopy) did not provide a clinical beneﬁ t 
when added to a limited workup, which included 
complete history taking and physical examination, 
complete blood counts, liver and kidney function 
tests, chest radiography, mammography (for women 
older than 50 years), Pap smear testing (for women 
18–70 years of age who had ever been sexually active), 
and prostate-speciﬁ c antigen test (for men older than 
40 years). The limited strategy missed four of 14 cancers 
diagnosed during the 1 year follow-up period, compared 
with ﬁ ve of 19 cancers with the extensive strategy. These 
results, together with other previous studies, have—for 
now—cooled the enthusiasm for cancer screening in 
patients with venous thrombosis.5,6
But when a door closes, another opens. In The Lancet 
Oncology, Philippe Robin and colleagues7 reignite 
the debate with the results of the ﬁ rst randomised 
trial comparing a limited screening strategy with the 
limited strategy plus ¹⁸F-ﬂ uorodeoxyglucose (¹⁸F-FDG) 
PET/CT for cancer screening in patients with unprovoked 
venous thromboembolism. ¹⁸F-FDG PET/CT seems an 
attractive tool to this aim because it is a non-invasive 
test that allows whole-body imaging and had shown 
high sensitivity in previous pilot studies.8,9
The number of occult malignancies detected with the 
limited screening strategy was four (2·0%) of 197 patients 
versus 11 (5·6%) of 197 in the ¹⁸F-FDG PET/CT group 
(absolute risk diﬀ erence 3·6%, 95% CI –0·4 to 7·9, 
p=0·065). But, importantly, during a 2-year follow-up of 
individuals with negative initial screening, a new cancer 
was diagnosed in only one (0·5%) of 186 patients in the 
¹⁸F-FDG PET/CT group compared with nine (4·7%) of 
193 patients in the limited strategy group (absolute risk 
diﬀ erence 4·1%, 95% CI 0·8 to 8·4, p=0·020).
Of note, as also happened in the SOME study, the 
observed overall rate of occult cancer was notably lower 
than expected (6% in this case). This might be explained 
by some characteristics of the study population—
eg, 25% of the patients were younger than 50 years, 
and 6% of the thrombotic events were associated 
with oral contraceptives. Interestingly, all but one of 
the malignancies found at initial screening or during 
Cancer screening after unprovoked venous thrombosis
be supported by the identiﬁ cation of biomarkers to 
recognise the high-risk minority of patients, especially 
those with a microscopic locoregional extension at 
the time of diagnosis of their primary melanoma. 
These patients might beneﬁ t from a wider, elective 
excision margin for their melanoma, or indeed, adjuvant 
therapies that might become the standard of care in 
the near future.
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